Blue Earth touts Axumin results in Lancet

2019 05 03 20 23 2154 Prostate 3 D 400

Bracco molecular imaging subsidiary Blue Earth Diagnostics is highlighting results of a study published in Lancet showing that postprostatectomy radiation therapy guided by the company's PET radiotracer Axumin (fluciclovine F-18) helped increase biochemical event-free survival rates in men with recurrent prostate cancer.-->

Of 165 patients whose prostate cancer returned following surgical removal of their prostate, the researchers found that 75.5% of those whose treatment was integrated Axumin PET imaging were event-free after three years, compared with 63% for whom only conventional imaging techniques were used to plan treatment, according to the company.

The study was published on 7 May and was led by researchers at the Winship Cancer Institute of Emory University in Atlanta.

Page 1 of 1249
Next Page